ABSTRACT. Streptococcus agalactiae (Lancefield group B; group B streptococci) is a major pathogen that causes meningoencephalitis Effective vaccines against the different serotypes or genotypes of pathogenic strains from the various hosts would be useful. We used an in silico strategy to identify conserved vaccine candidates in 15 genomes of group B streptococci strains isolated from human, bovine, and fish samples. The degree of conservation, subcellular localization, and immunogenic potential of S. agalactiae proteins were investigated. We identified 36 antigenic proteins that were conserved in all 15 genomes. Among these proteins, 5 and 23 were shared only by human or fish strains, respectively. These potential vaccine targets may help develop effective vaccines that will help prevent S. agalactiae infection.
INTRODUCTION
Streptococcus agalactiae (Lancefield group B; GBS) is a major bacterial pathogen that causes diseases in humans, cattle, and fish (Brochet et al., 2006; Mian et al., 2009) . In humans, it is frequently associated with neonatal sepsis and meningitis, but can also affect immunocompromised adults, besides also being a common colonizer of the gastrointestinal and genitourinary tracts (Park et al., 2012) . In dairy cattle, GBS is an important pathogen of clinical and subclinical mastitis, affecting milk quality and production (Richards et al., 2011) . In fish, S. agalactiae is an emerging pathogen that causes septicemia and meningoencephalitis with high mortality in wild and cultured species worldwide (Mian et al., 2009; Chen et al., 2012) .
Preventive measures are taken to prevent GBS infection in humans, such as intrapartum antibiotic prophylaxis. But this practice is only effective in early-onset disease (0 to 7 days of life), while having no impact on late-onset disease (7 to 90 days postpartum), where the infection can still occur, and it is not practical in nonpregnant adults (Edmond et al., 2012) . In animal production, the extensive use of antibiotics is not permitted in many countries and may compromise the economic viability of the practice and safety of those products (Mitchell et al., 1998; Cañada-Cañada et al., 2009) .
Thus, immunoprophylaxis strategy is the most viable option to reduce the damage caused by this pathogen in human health and animal production (Maione et al., 2005; Nuccitelli et al., 2011) . Several types of vaccine formulations have been tested for use in humans, such as whole-cell inactivated bacteria, capsular carbohydrates, and recombinant proteins present on the bacterial surface. However, there have been relatively few clinical trials with GBS vaccines in the last years (Heath, 2011) . Capsular polysaccharide (CPS)-based vaccines, developed using serotypes II and III conjugated with tetanus toxoid, have been shown to be safe and immunogenic in humans. However, this formulation has shown little or no cross-protection against other serotypes (Johri et al., 2006) . Additionally, fur-ther studies are needed to investigate vaccine efficacy when more than two GBS CPS types are simultaneously administered (Paoletti and Madoff, 2002) . Another limiting factor in CPS vaccination is the significant prevalence of nontypeable CPS strains, which may compromise its efficacy (Baker and Edwards, 2003) .
The use of conserved antigenic proteins has been emerging as a useful alternative in the development of vaccines against many bacterial pathogens including GBS (Maione et al., 2005; He et al., 2010; Soares et al., 2012) . The bioinformatic tools currently available allow us to predict many features of all proteins present in the genome such as subcellular localization, conservation degree (when other genomes of the same species are analyzed), and antigenic potential (MHC I and II epitope predictions) (He et al., 2010) .
A previous study evaluated the genome sequences of eight human strains of S. agalactiae to identify potential surface-exposed proteins in core and accessory genomes to be used as vaccine candidates. Only 4 of 312 candidates tested showed protection in in vivo experiments, and from these, only 1 belonged to the core genome (Maione et al., 2005) . The in silico immunogenicity of these proteins was not evaluated, which may explain the low efficiency of the majority of tested targets. Currently, other GBS genomes were deposited in GenBank, including strains isolated from other hosts such as cattle and fish (Richards et al., 2011; Delannoy et al., 2012; Liu et al., 2012; Wang et al., 2012; Pereira et al., 2013) . Furthermore, new tools for vaccine target prediction are available that estimate the immunogenic potential of proteins, which may improve the choice (and reduce the number) of vaccine targets to be tested (He et al., 2010) . Thus, the prediction of conserved immunogenic proteins may help in finding new and efficient candidates for vaccine development.
There are few studies of vaccines against mastitis caused by S. agalactiae, because this is usually easy to control through hygiene and treatment measures (Duarte et al., 2004) . However, a study that used the conserved Sip protein along with one S. aureus protein (ClfA protein) showed higher efficacy of this chimeric vaccine when compared with the inactivated vaccine of each one of these pathogens in experimental challenge in lactating mice (Xu et al., 2011) . In fish, bacterial vaccines against GBS have already been tested and are commercially available. However, vaccine protection was demonstrated to be variable between strains of the same serotype and different genotypes, suggesting that the capsule is not the single antigen to elicit immune response in fish (Chen et al., 2012) .
This study aimed to perform a comparative genomic analysis to identify the core genes of 15 S. agalactiae strains isolated from humans, cattle, and fish, and moreover, to find conserved antigenic proteins to be used in the development of vaccines against GBS infection in these hosts.
MATERIAL AND METHODS

Genome sequences
The complete and draft genome sequences of 15 S. agalactiae strains were retrieved from the NCBI database (http://www.ncbi.nlm.nih.gov/genbank/): 10 strains isolated from humans (three complete genomes), 1 strain isolated from cow (draft genome), and 4 strains isolated from fish (2 complete genomes) ( Table 1 ). The human strains were isolated in USA, Italy, Canada, United Kingdom, or unknown country. These strains were isolated from clinical cases of septicemia and meningitis or from body sites of healthy person (colonizing the oral cavity or vagina). The bovine strain was isolated from clinical mastitis in the USA, and the fish strains were isolated from meningoencephalitis outbreaks in China, Brazil, and Honduras ( 
Prediction of core genes
The identification of all genes of the S. agalactiae species and conserved genes (core genes) between the 15 genomes analyzed was performed using the EDGAR (version 1.2) software (Blom et al., 2009) . EDGAR is a framework for the comparative analysis of prokaryotic genomes that performs homology analyses based on a specific cut-off that is automatically adjusted to the query dataset. Briefly, the genome sequences of S. agalactiae were retrieved from GenBank; the homogenization of the genome annotations was conducted by GenDB (version 2.4) (Meyer et al., 2003) ; an EDGAR project was created; and homology calculations based on BLAST Score Ratio Values at the protein level were performed resulting in all genes representative of the species (pan-genome), genes shared by all (or a group) strains (core genes), accessory and strain-specific genes.
Prediction of vaccine candidates
The prediction of cross-reactive vaccine candidates was performed similarly as with the criteria described by Soares et al. (2012) . The potential targets had to present the following attributes: rule I) to be exposed to the host immune system, such as secreted, surface-exposed, and membrane proteins (Rappuoli, 2001) ; rule II) to show MHC I and II binding properties with adhesion probability greater than 0.51 and no similarity to human proteins when analyzed by the Vaxign software (He et al., 2010) ; rule III) protein conservation among different genomes of S. agalactiae in all 15 strains or in genomes of human or fish strains (He et al., 2010; Soares et al., 2012) .
The subcellular localization of proteins (rule I) was predicted by an in silico analysis using the SurfG+ 1.0 tool (Barinov et al., 2009) , where a multi-FASTA file of the pangenome of 15 genomes of S. agalactiae was analyzed. SurfG+ pipeline searches protein motifs, including SignalP, LipoP, and TMHMM, which are related to subcellular localization. It also creates novel HMMSEARCH profiles to predict cell wall retention signals. Afterwards, it looks for retention signals, lipoproteins, SEC (secreted proteins) pathway export motifs, and transmembrane motifs. The proteins were characterized as cytoplasmic (CYT) if none of these motifs were found in their sequences. Moreover, SurfG+ has the ability to better distinguish between MEM (membrane proteins) and PSE (potentially surface-exposed proteins), which may assist in the choice of possible vaccine targets. Proteins could thereby be classified into four different subcellular locations: CYT, MEM, PSE, or SEC. The SurfG+ software uses cell wall thickness to better differentiate integral membrane proteins from PSE proteins. This measure was performed for the NEM316 human strain and SA20-06 fish strain by transmission electron microscopy EM10A equipment (Zeiss) according to Barinov et al. (2009) . Briefly, S. agalactiae strains were streaked on blood agar and incubated at 30°C for 48 h. Subsequently, these strains were grown in 100 mL brain heart infusion broth at 30°C for 24 h. After centrifugation, the pellet was fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.2, for 18 h at 4°C. The samples were post-fixed in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer, pH 7.2, + 1.5% potassium ferrocyanide for 90 min, dehydrated in a graded ethanol series (30-100%), and embedded in Eponate-Araldite resin. Ultrathin sections were obtained using uranyl acetate and lead citrate and later examined in a Zeiss-EM-10A. Microphotographs were obtained using a CCD Mega view III camera. The means of the cell wall of human strain NEM316 and fish strain SA20-06 were performed by more than 100 measurements in at least five photographs of each strain.
To apply rule II, the proteins predicted by SurfG+ as SEC, PSE, and MEM were analyzed by the Vaxign software (He et al., 2010) . The software evaluates adhesion probability and protein conservation between different genomes in the OrthoMCL database, and excludes sequences of nonpathogenic strains or host-similar proteins. S. agalactiae proteins with high similarity to human proteins were excluded from the analysis.
As one of the aims of this study was to search for conserved vaccine candidates, the proteins predicted by the EDGAR software in the core genome of all strains or proteins conserved only in human or fish strains were considered to conform to rule III. However, the conservation of proteins (rule III) does not exclude the antigenic target, since a universal vaccine described in a previous study (Maione et al., 2005) had consisted of proteins of the accessory genome. Additionally, some antigenic proteins of the accessory genome can be good vaccine targets against more prevalent serotypes in a given specific geographic region or host.
RESULTS
The total number of genes found in the 15 genomes of S. agalactiae strains iso-Prediction of vaccine targets in Streptococcus agalactiae lated from humans, cattle, and fish was 5143. A total of 1111 genes were shared by all strains, while 1297 and 1523 genes were shared by human or fish strains, respectively. The mean cell wall measure of fish strain SA20-06 and human strain NEM316 was 18.67 and 19.12 nm, respectively. Thus, due to the high similarity of these values in both human and fish strains, an approximate value of 19 nm was used to perform the SurfG+ analysis (Figure 1) . The SurfG+ analyses of 5143 predicted proteins from the pan-genome of all the 15 strains of S. agalactiae identified 156 SEC proteins, 398 PSE proteins, 773 MEM proteins, and 3816 CYT proteins. The 1327 proteins classified as SEC, PSE, or MEM (rule I) were evaluated by the Vaxign software, and 150 showed an adhesion probability greater than 0.51 (Table S1 ). Eight of these 150 proteins (SAK_1493, SAI_0146, SAK_0722, SAK_0477, SAK_0477, SAK_2135, SAK_0084, and SAK_0084) were shown to be similar to mammalian proteins and were excluded from the analyses ( Table S1) .
Of those 142 proteins, 36 were present in the core genome of the 15 S. agalactiae strains fulfilling all rules of vaccine candidates proposed here. A total of 41 candidates were found to be conserved in genomes of human isolates (Table 2 ). Of these, 5 proteins (SAK_0050, SAK_1293, SAK_1319, SAK_066, and SAK_1074) were exclusively found in the strains of this host. Fifty-nine protein candidates were found in core genes of fish strains. Of these, 23 proteins were shared only by fish strains (Table 2) .
DISCUSSION
The development of broad protective vaccines is highly needed to control GBS infections mainly in humans and fish, since prophylactic measures are frequently effective in bovine infections. Additionally, different pathogenesis mechanisms may be related to disease U.P. Pereira et al. 
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in cattle when compared with humans and fish, since the bovine disease is limited to mammary glands (Richards et al., 2011) . Furthermore, the genome sequence of only one strain is not enough to understand the biology of this GBS bovine subpopulation and to perform the prediction of vaccine candidates specifically for this host. Similarly, differences in the immune response between humans and fish may also result in a variable efficacy of vaccine targets in these different hosts.
Thirty-six shared proteins in all 15 GBS genomes is a discrepant number when compared with the study of Maione et al. (2005) , which identified 396 vaccine candidate proteins shared by genomes of 8 human strains. It is mainly due to the adhesion probability score of the Vaxign software, which predicts the presence of immunogenic epitopes for MHC I and II in the proteins analyzed, eliminating protein candidates with low scores. Another factor is the greater number of genomes currently available, which results in a lower number of core genes. The large number of vaccine targets to be tested is expensive and tedious. Thus, the use of in silico prediction of immunogenicity of proteins may provide better selection and reduce the number of vaccine targets. Among the 36 vaccine candidates found here, in silico prediction identified a well-characterized immunogenic protein Sip (GBS surface immunogenic protein). Penicillinbinding protein 1A and zoocin A are two other identified proteins that deserve attention, due to their high potential as vaccine candidates. In addition, the genes conserved only in human or fish strains may be evaluated as possible candidates to host specific vaccines ( Table 2) .
The Sip protein (SAK_0065) was the only protein of the core genome that resulted in protection in experimental challenge in the study of Maione et al. (2005) . Here, this protein was also classified among the best five vaccine targets according to adhesion probability predicted by the Vaxign software. The penicillin-binding proteins have a traditional function in the biosynthesis of cell wall peptidoglycan. In addition, the penicillin-binding protein 1A (SAK_0370) has been related to resistance of GBS to phagocytosis and antimicrobial peptides (Hamilton et al., 2006 son et al., 2007) . In core genes of human S. agalactiae strains, the PcsB protein (SAK_0050) is a secreted protein with pivotal function in cell division and antibiotic tolerance in GBS. The inactivation of this gene results in abnormal cell division and reduction of tolerance to osmotic pressure and antibiotics (Reinscheid et al., 2001) . The virulence factor laminin-binding protein (SAK_1319) was also predicted as a vaccine target in core genome of human strains. In S. agalactiae, this protein is related to adhesion and invasion of host tissues, and due to its 3-D structure features, was suggested as a good vaccine target (Ragunathan et al., 2009) .
Currently, three distinct pilus islands (PIs) have been characterized in S. agalactiae and the presence of these PIs is variable in the genome of different strains. Pilus proteins have been described as having a key role in S. agalactiae pathogenesis (Maisey et al., 2007; Konto-Ghiorghi et al., 2009 ) and have been proposed as good vaccine candidates (Sharma et al., 2013) . Although the pilus proteins do not belong to the core genome of all 15 strains of S. agalactiae, promising results in development of universal vaccines have been proposed by a combination of immunogenic pilus proteins of three PIs (Margarit et al., 2009) . Additionally, the PI-2b was present in all four fish strains, suggesting that a vaccine developed by proteins of this PI may be effective against the disease in fish, mainly using the backbone protein or ancillary protein 1, which showed higher adhesion probability (Table 2) . A previous study demonstrated that backbone protein and ancillary protein 1 of PI-2b conferred protection in experimental challenge (Margarit et al., 2009) , and the in silico prediction carried out here suggests that these proteins are good vaccine candidates (Table 2) . Additionally, in this previous study, ancillary protein 2 was not found on the bacterial surface and did not confer protection in experimental challenge. Similarly, this protein (SAK_1438 -ancillary protein 2) was not suggested by in silico analysis performed here as a good vaccine candidate due to the low adhesion probability score observed ( Table S1 ).
The CAMP factor protein was shared only by fish strains. It is a known virulence factor described for S. agalactiae, and is a secreted protein that forms pores in the host cell, promoting damage and tissue invasion (Rajagopal, 2009 ). This protein was absent only in a draft genome of S. agalactiae human strain CJB111, suggesting that the sequence fragment that harbors this protein might not have been represented in genome assembly. Thus, CAMP factor probably may be a good vaccine target against GBS infection in both hosts.
Concerning the proteins with unknown function or not still tested as a vaccine target, future studies have to be carried out to evaluate the protection elicited by those candidates in experimental challenge in mice, cattle, and/or fish. Furthermore, these proteins may be related to the virulence of S. agalactiae in these hosts, and their characterization could provide new insights into GBS infection and pathogenesis. Therefore, the vaccine targets predicted here open doors to new studies of functional characterization of proteins (mainly related to interaction with host) and vaccine development.
